ORGO Stock Analysis: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$2.34
-0.03 (-1.27%)
▼
5d:
-8.24%
30d:
-0.85%
90d:
-8.95%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ORGO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ORGO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $2.34, which is considered oversold relative to its 30-day fair value range of $2.37 to $2.56. From a valuation perspective, the stock is trading at a discount (Forward PE: -8.5) compared to its historical average (18.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ORGO is showing sideways momentum. The price is currently testing key support at $2.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.00 (+28.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ORGO is showing sideways momentum. The price is currently testing key support at $2.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.00 (+28.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.37 -
$2.56
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.2% below Wall St target ($3.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -8.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.37 -
$2.56
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.26
(11.2%)
Support & Resistance Levels
Support Level
$2.30
Resistance Level
$2.69
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.51
Wall Street Target
$3.00
(+28.2%)
Revenue Growth (YoY)
-57.1%
Earnings Growth (YoY)
555.2%
Profit Margin
0.5%
PE vs Historical
-8.5 vs 18.1
CHEAP
Share & Embed Analysis
Last updated: August 03, 2026 9:55 PM ET
Data refreshes hourly during market hours. Next update: 10:55 PM
Data refreshes hourly during market hours. Next update: 10:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Arthur S Leibowitz
BUY
5000 shares
2026-03-09
Michael Joseph Driscoll
BUY
10000 shares
2026-03-09
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
